Evaluating the Efficacy of a Novel Endometrial Receptivity Analysis Test in Improving Pregnancy Outcomes for Chinese IVF Patients: A Single-Center Retrospective Study

Background The current data about whether endometrial receptivity test could improve the pregnancy outcomes for Chinese IVF patients is conflicting and limited. This single-center retrospective study evaluated the efficacy of HerRecepta, a novel transcriptomic endometrial receptivity test in guiding personalized embryo transfer (pET) for Chinese IVF patients, with a focus on RIF and clinical factors influencing window of implantation (WOI). Methods This retrospective study included 220 IVF patients who underwent HerRecepta testing. Endometrial biopsies were analyzed via RNA sequencing to determine receptivity status (receptive/non-receptive), and pregnancy outcomes after frozen embryo transfer (FET) were compared between standard and personalized FET (pET) groups. Results Of 220 patients, 43.6% had non-receptive endometria (71.9% pre-receptive). Advanced age (> 35 years) and high AMH levels were risk factors for non-receptivity. Among 200 FET cases, overall pregnancy rate (PR), clinical pregnancy rate (CPR), and live birth rate (LBR) were 53.50%, 46.50%, and 32.11%, respectively. Non-receptive (pET) group showed comparable clinical outcomes to the receptive (standard ET) group in PR (51.82% vs. 55.56%, P  = 0.49), CPR (46.36% vs. 46.67%, P  = 0.96), and LBR (32.38% vs. 31.76%, P  = 0.93. Similar results were observed in the RIF subgroup (124 patients). Conclusion Our findings suggest that HerRecepta test can be a valuable tool for personalized embryo transfer in IVF, particularly in specific subgroups with advanced age and with high AMH levels. Future studies to validate the optimal indication of endometrial receptivity test are needed.